5AM Ventures

At 5AM Ventures, our greatest privilege is in backing strong science that translates to meaningful new medicines. This week, our longtime Venture Partner Mason Freeman and his co-authors published clinical results in the New England Journal of Medicine demonstrating the effects of baxdrostat in patients with primary hyperaldosteronism—coinciding with AstraZeneca’s announcement of positive Phase 3 results in resistant hypertension. Originally developed by CinCor Pharma, Inc., a 5AM portfolio company acquired by AstraZeneca, baxdrostat represents the kind of rigorous science, translational leadership, and a clear path to impact for patients that 5AM is focused on. Since 5AM’s initial investment in CinCor, Mason played a significant role in driving diligence and led all clinical development as CinCor's Chief Medical Officer, reflecting the depth of expertise we embed across our portfolio and our commitment to advancing breakthrough therapeutics. Congratulations Mason! Read the full NEJM article here: https://lnkd.in/eiVj_ffx

Congratulations to the team at Fellow on closing a $24M Series B to expand access to high-quality at-home testing for male reproductive health. We at 5AM Ventures are proud to lead this round and support Fellow’s mission to bring clarity, convenience, and clinical rigor to an area of health that has long been underserved. Excited to partner alongside The Forest Road Company, and other outstanding investors in this next chapter. https://lnkd.in/e2fNBgRk

Huge congratulations to the entire team at Renasant Bio for launching with $54.4M in seed financing. With a world-class team led by Emily Conley and deep expertise in ADPKD, we believe Renasant is poised to make a transformative impact. Born out of the 4:59 NewCo, a 5AM Ventures Company, we're proud to have led this round alongside Atlas Venture, OrbiMed, and Qiming Venture Partners to support the development of next-generation, disease-modifying small molecule therapies for ADPKD patients. https://lnkd.in/e4GzGekh

We are seeking candidates for our first ever Artificial Intelligence/Machine Learning (AI/ML) Fellow based in our Boston office to help evaluate emerging and existing AI/ML approaches for for drug and clinical development and identify opportunities for AI/ML biotech venture investments. If you have a strong computer science background with hands on experience in life science or healthcare AI/ML applications, please consider applying. For more information and to apply, visit: https://lnkd.in/eC58sDTF

Today, we announced updated, positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with #CML. The data will be presented in an oral presentation at the #EHA2025 congress taking place in Milan Italy, and virtually. ELVN-001 Data Highlights: - 25 of 53 (47%) evaluable patients were in MMR by 24 weeks, with 13 of 41 (32%) achieving and 12 of 12 (100%) maintaining MMR. - Of those resistant to their last TKI, 14 of 34 (41%) were in MMR by 24 weeks.  - Of those previously treated with asciminib or ponatinib 12 of 34 (35%) were in MMR by 24 weeks. - All patients who achieved or maintained MMR were still in MMR at the time of data cutoff - These data continued to compare favorably to precedent Phase 1 MMRs for approved BCR::ABL1 TKIs, particularly given the more heavily pretreated patient population in the ELVN-001 clinical trial. - ELVN-001 remains well-tolerated across all evaluated doses. For full details, read today’s press release here: https://bit.ly/4jSfVMX and listen to our company webcast at 1:30pm ET: https://bit.ly/445PPQL #EHA2025 #Oncology #PrecisionTherapeutics

This morning, Rallybio announced the initiation of dosing in a Phase 1 confirmatory PK/PD study evaluating RLYB116. Additionally, Rallybio announced that the initial indication focus for RLYB116 will be on two hematologic conditions with significant unmet need: immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Patients suffering from these potentially life-threatening conditions have no approved or effective therapeutic options. Read our press release here: http://bit.ly/3SOTPjm

Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025. Read the press release here: https://lnkd.in/eBNk-AQk

TMRW has acquired CRYOGATT SYSTEMS LIMITED’s patent portfolio, including RFID technologies designed for cryogenic storage systems with integrated sensor and tracking capabilities. Read the full announcement → https://lnkd.in/evcBaCrt This acquisition accelerates our ability to keep innovating, expanding, and raising the standard of care for the management and storage of life’s most precious cells. It provides the foundational technology to accelerate the development of several next-generation TMRW solutions: 🔹 Enhanced digital management for non-TMRW storage tanks 🔹 Expanded digitally integrated sperm storage solutions 🔹 A more robust audit trail for select storage offerings TMRW already integrates and is compatible with all major EMRs and witnessing systems—eliminating double data entry and streamlining workflows. Now, we’re building on that foundation to support our partner clinics, their growing inventories, and the evolving needs of every IVF lab. “These patents help lay the foundation for the next generation of TMRW’s digital solutions. We’re continuing to expand our product offering to support each fertility clinic’s unique needs—whether they’re upgrading existing infrastructure or seeking new ways to modernize their specimen storage.” - Cynthia Hudson, Head of Clinical Strategy, TMRW Life Sciences “As demand for fertility treatments continues to grow, clinics need solutions that are not only scalable but also raise the standard of care. This acquisition reflects our commitment to continued innovation and to supporting clinics with technology that goes beyond what’s required today. We’re focused on helping the industry meet this moment—and what comes next.” - Louis Villalba, CEO, TMRW Life Sciences #ItsTimeForTMRW #BuiltForYou

We have reached a major milestone, dosing the first patients in our Phase 2 RESOLVE-1 #ClinicalTrial, investigating the therapeutic potential of NT-0796, our oral #NLRP3 #inflammasome inhibitor, in patients with #obesity. Our earlier research has demonstrated that NLRP3, a master switch of #inflammation, plays a key role in controlling obesity and obesity-associated inflammation. NT-0796 is designed to target chronic inflammation at its source and address the complex biology of weight regulation, aiming to restore metabolic balance and enable sustained, healthy weight loss. Following our recently closed $50 million Series D financing, we’re excited to accelerate this lead program through a robust Phase 2 trial. Learn more here: https://lnkd.in/e5yu6amC #Biotech #NodThera #Innovation #Data

Today, we are pleased to announce the appointment of Maha Radhakrishnan, M.D. to our Board of Directors.   “We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Maha’s deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.   Read the full release: https://lnkd.in/epCUtjFP   You can also check out our website for recent updates to our Corporate Presentation: https://lnkd.in/e4eBUv5i   #Biotech #DMD #Duchenne